市場調查報告書

全球裘馨氏肌肉萎縮症治療藥市場

Duchenne Muscular Dystrophy Drugs

出版商 Global Industry Analysts, Inc. 商品編碼 893737
出版日期 內容資訊 英文 94 Pages
商品交期: 最快1-2個工作天內
價格
全球裘馨氏肌肉萎縮症治療藥市場 Duchenne Muscular Dystrophy Drugs
出版日期: 2020年02月01日內容資訊: 英文 94 Pages
簡介

本報告提供全球裘馨氏肌肉萎縮症治療藥市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業簡介等相關資訊彙整。

第1章 調查方法

第2章 摘要整理

  • 市場概要
    • 裘馨氏肌肉萎縮症治療藥市場顯示堅固成長的市場
    • 全球競爭企業的市場佔有率
    • 全球市場佔有率方案
    • 各分類市場佔有率
    • 變異抑制
    • 外顯子跳躍
    • 全球市場趨勢
    • 治療概要與近幾年的發展
    • 治療所使用的類固醇
    • 對幼兒Translarna表現有利的結果
    • 比Emflaza皮質類固醇可保存更佳運動功能透過臨床實驗清楚證實
    • 臨床實驗表示 Golodirsen增加患者的抗肌萎縮蛋白產生
    • FDA核准裘馨氏肌肉萎縮症治療用的皮質類固醇Emflaza
  • 主要參與企業
  • 市場趨勢和促進因素
  • 全球市場預測

第3章 市場分析

  • 各地區市場分析
  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲各國
  • 亞太地區
  • 其他各國

第4章 競爭

  • ACCELERON PHARMA
  • AKASHI THERAPEUTICS
  • BIOMARIN PHARMACEUTICAL
  • BRISTOL-MYERS SQUIBB COMPANY
  • ELI LILLY AND COMPANY
  • JANSSEN PHARMACEUTICALS
  • LEXICON PHARMACEUTICALS
  • 株式會社日本觸媒
  • NOBELPHARMA
  • PTC THERAPEUTICS
  • PFIZER
  • SAREPTA THERAPEUTICS
  • 大鵬藥品工業株式會社

第5章 相關調查

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP11652

Duchenne Muscular Dystrophy Drugs market worldwide is projected to grow by US$4.9 Billion, driven by a compounded growth of 40.5%. Mutation Suppression, one of the segments analyzed and sized in this study, displays the potential to grow at over 39%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$1.9 Billion by the year 2025, Mutation Suppression will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 45% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$141.4 Million to the region's size and clout in the next 5 to 6 years. Over US$226.5 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Mutation Suppression will reach a market size of US$144.6 Million by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 38.9% over the next couple of years and add approximately US$809.3 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include, among others,

  • Acceleron Pharma, Inc.
  • Akashi Therapeutics, Inc.
  • BioMarin Pharmaceutical, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Janssen Pharmaceuticals, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Nippon Shokubai Co., Ltd.
  • Nobelpharma Co., Ltd.
  • Pfizer, Inc.
  • PTC Therapeutics, Inc.
  • Sarepta Therapeutics Inc.
  • Taiho Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Duchenne Muscular Dystrophy (DMD) Drugs Market To Exhibit Strong Growth
  • Global Competitor Market Shares
  • Duchenne Muscular Dystrophy Drugs Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
  • Global Market Dynamics
  • Treatment Overview and Recent Developments
  • Steroids used for the Treatment of DMD
  • Translarna Exhibits Positive Result in Children with DMD
  • Clinical Trials Depict Emflaza Preserves Motor Function Better than Corticosteroids
  • Trial Shows Golodirsen Increases Dystrophin Production in DMD Patients
  • Casimersen and Golodirsen Exhibits Positive Results in Sarepta's ESSENCE study
  • EXONDYS 51(r) Drug Details
  • FDA Approves Corticosteroid Emflaza for Treating DMD Patients

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

  • Pipeline Analysis
  • Drug Price Details: Exondys51
  • Sarepta's DMD Gene Therapy Trial Update

4. GLOBAL MARKET PERSPECTIVE

  • TABLE 1: Duchenne Muscular Dystrophy Drugs Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025
  • TABLE 2: Duchenne Muscular Dystrophy Drugs Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017
  • TABLE 3: Duchenne Muscular Dystrophy Drugs Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025
  • TABLE 4: Mutation Suppression (Segment) World Market by Region/Country in US$ Thousand: 2018 to 2025
  • TABLE 5: Mutation Suppression (Segment) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017
  • TABLE 6: Mutation Suppression (Segment) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 7: Exon Skipping (Segment) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025
  • TABLE 8: Exon Skipping (Segment) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017
  • TABLE 9: Exon Skipping (Segment) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
  • TABLE 10: Other Segments (Segment) Geographic Market Spread Worldwide in US$ Thousand: 2018 to 2025
  • TABLE 11: Other Segments (Segment) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2009 to 2017
  • TABLE 12: Other Segments (Segment) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • Market Facts & Figures
    • US Duchenne Muscular Dystrophy Drugs Market Share (in %) by Company: 2019 & 2025
    • Market Analytics
    • TABLE 13: United States Duchenne Muscular Dystrophy Drugs Market Estimates and Projections in US$ Thousand by Segment: 2018 to 2025
    • TABLE 14: Duchenne Muscular Dystrophy Drugs Market in the United States by Segment: A Historic Review in US$ Thousand for 2009-2017
    • TABLE 15: United States Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • CANADA
    • TABLE 16: Canadian Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018 to 2025
    • TABLE 17: Canadian Duchenne Muscular Dystrophy Drugs Historic Market Review by Segment in US$ Thousand: 2009-2017
    • TABLE 18: Duchenne Muscular Dystrophy Drugs Market in Canada: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025
  • JAPAN
    • TABLE 19: Japanese Market for Duchenne Muscular Dystrophy Drugs: Annual Sales Estimates and Projections in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 20: Duchenne Muscular Dystrophy Drugs Market in Japan: Historic Sales Analysis in US$ Thousand by Segment for the Period 2009-2017
    • TABLE 21: Japanese Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • CHINA
    • TABLE 22: Chinese Duchenne Muscular Dystrophy Drugs Market Growth Prospects in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 23: Duchenne Muscular Dystrophy Drugs Historic Market Analysis in China in US$ Thousand by Segment: 2009-2017
    • TABLE 24: Chinese Duchenne Muscular Dystrophy Drugs Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • EUROPE
    • Market Facts & Figures
    • European Duchenne Muscular Dystrophy Drugs Market: Competitor Market Share Scenario (in %) for 2019 & 2025
    • Irish Boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) Gains Access to Key, Life-Supporting Drug
    • CHMP Rejects Exondys 51 in Europe
    • Market Analytics
    • TABLE 25: European Duchenne Muscular Dystrophy Drugs Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025
    • TABLE 26: Duchenne Muscular Dystrophy Drugs Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017
    • TABLE 27: European Duchenne Muscular Dystrophy Drugs Market Share Shift by Region/Country: 2009 VS 2019 VS 2025
    • TABLE 28: European Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018-2025
    • TABLE 29: Duchenne Muscular Dystrophy Drugs Market in Europe in US$ Thousand by Segment: A Historic Review for the Period 2009-2017
    • TABLE 30: European Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • FRANCE
    • TABLE 31: Duchenne Muscular Dystrophy Drugs Market in France by Segment: Estimates and Projections in US$ Thousand for the Period 2018-2025
    • TABLE 32: French Duchenne Muscular Dystrophy Drugs Historic Market Scenario in US$ Thousand by Segment: 2009-2017
    • TABLE 33: French Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • GERMANY
    • TABLE 34: Duchenne Muscular Dystrophy Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 35: German Duchenne Muscular Dystrophy Drugs Historic Market Analysis in US$ Thousand by Segment: 2009-2017
    • TABLE 36: German Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • ITALY
    • TABLE 37: Italian Duchenne Muscular Dystrophy Drugs Market Growth Prospects in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 38: Duchenne Muscular Dystrophy Drugs Historic Market Analysis in Italy in US$ Thousand by Segment: 2009-2017
    • TABLE 39: Italian Duchenne Muscular Dystrophy Drugs Market by Segment: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • UNITED KINGDOM
    • TABLE 40: United Kingdom Market for Duchenne Muscular Dystrophy Drugs: Annual Sales Estimates and Projections in US$ Thousand by Segment for the Period 2018-2025
    • TABLE 41: Duchenne Muscular Dystrophy Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Segment for the Period 2009-2017
    • TABLE 42: United Kingdom Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • REST OF EUROPE
    • TABLE 43: Rest of Europe Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018-2025
    • TABLE 44: Duchenne Muscular Dystrophy Drugs Market in Rest of Europe in US$ Thousand by Segment: A Historic Review for the Period 2009-2017
    • TABLE 45: Rest of Europe Duchenne Muscular Dystrophy Drugs Market Share Breakdown by Segment: 2009 VS 2019 VS 2025
  • ASIA-PACIFIC
    • TABLE 46: Duchenne Muscular Dystrophy Drugs Market in Asia-Pacific by Segment: Estimates and Projections in US$ Thousand for the Period 2018-2025
    • TABLE 47: Asia-Pacific Duchenne Muscular Dystrophy Drugs Historic Market Scenario in US$ Thousand by Segment: 2009-2017
    • TABLE 48: Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share Analysis by Segment: 2009 VS 2019 VS 2025
  • REST OF WORLD
    • TABLE 49: Rest of World Duchenne Muscular Dystrophy Drugs Market Estimates and Forecasts in US$ Thousand by Segment: 2018 to 2025
    • TABLE 50: Rest of World Duchenne Muscular Dystrophy Drugs Historic Market Review by Segment in US$ Thousand: 2009-2017
    • TABLE 51: Duchenne Muscular Dystrophy Drugs Market in Rest of World: Percentage Share Breakdown of Sales by Segment for 2009, 2019, and 2025

IV. COMPETITION

  • ACCELERON PHARMA
  • AKASHI THERAPEUTICS
  • BIOMARIN PHARMACEUTICAL
  • BRISTOL-MYERS SQUIBB COMPANY
  • ELI LILLY AND COMPANY
  • JANSSEN PHARMACEUTICALS
  • LEXICON PHARMACEUTICALS
  • NIPPON SHOKUBAI
  • NOBELPHARMA
  • PTC THERAPEUTICS
  • PFIZER
  • SAREPTA THERAPEUTICS
  • TAIHO PHARMACEUTICAL

V. CURATED RESEARCH